Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1356 DM926, a novel anti-LILRB1/LILRB2 dual antagonist antibody, promotes adaptive and innate immune response to enhance anti-tumor activity in preclinical models
Compose a Response to This Article
Other responses
No responses have been published for this article.
